Is UroGen Pharma Ltd. (URGN) a Buy, Sell, or Hold?
UroGen Pharma Ltd.
NASDAQ:URGN
$39.19 USD
-$0.32 (-0.81%)
- Volume
- 478.65K
- Average Volume
- 814.44K
- Market Capitalization
- $1.91B
- P/E Ratio
- -14.25
- Dividend Yield
- 0.00%
- Price Target
- $42.50
- Year High
- $40.35
- Year Low
- $13.79
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.69
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Elizabeth Barrett |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | URGN |
| CUSIP | M95172105 |
| CIK | 0001668243 |
| Web | https://www.urogen.com |
| Phone | 646 768 9780 |
| Currency | USD |
| Employees | 291 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.59 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.69 |
| Quick Ratio | 4.28 |
| Cash Ratio | 2.20 |
Sales & Book Value
| Annual Sales | $109.79M |
| Price / Sales | 13.59 |
| Cash Flow | -3.31 |
| Price / Cash Flow | -11.50 |
| Price / Book | -15.83 |
Price Target and Rating
| Average Stock Price Forecast | $42.50 |
| High Stock Price Forecast | $45.00 |
| Low Stock Price Forecast | $40.00 |
| Forecast Upside/Downside | -7.79% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 15 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-3.19 |
| Trailing P/E Ratio | -14.25 |
| PEG Ratio | -1.16 |
| P/E Growth | -1.16 |
| Net Income | $-153.49M |
| Net Margin | -94.83% |
| Pretax Margin | -98.45% |
| Return on Equity | 121.52% |
| Return on Assets | -52.51% |
Financials Score
| AltmanZ Score | -2.45 |
| Piotroski Score | 2.00 |
| Working Capital | 186.83M |
| Total Assets | 253.69M |
| Ebit | -118.34M |
| Market Cap | 1.94B |
| Total Liabilities | 377.94M |
Poll Results
About UroGen Pharma Ltd. (NASDAQ:URGN) Stock
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several for ... ms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
2026-07-12 14:11:56
According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds. The sale represented 8% of the insider's direct equity holdings in the company, as reported in the Form 4.
2026-07-08 08:00:00
FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient enrollment expected to begin in Q4 2026 UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation PRINCETON, N.J., July 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Urogen Pharma (URGN) is a Great Momentum Stock: Should You Buy?
2026-07-07 13:01:17
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Let Go of 10,000 Shares?
2026-06-30 23:38:01
10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $35.01 per share on June 22, 2026. The sale represented 7.15% of Mark Schoenberg's direct holdings, reducing his position from 139,763 to 129,763 shares of common stock.
Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
2026-06-14 11:14:38
5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weighted average price around $27.30 per share. The transaction represented 3.60% of Mark Schoenberg's direct holdings, reducing his position from 144,985 to 139,763 shares.
2026-06-10 14:42:17
UroGen Pharma Ltd. (URGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-05 08:00:00
PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
2026-06-02 08:00:00
Agreement reinforces the value of UroGen's innovation and reflects the strength of the Company's intellectual property portfolio Teva will be granted a non-exclusive license to sell its generic version of JELMYTO beginning on September 15, 2030, if approved by the FDA PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Frequently Asked Questions
-
What is the current UroGen Pharma Ltd. (URGN) stock price?
-
UroGen Pharma Ltd.(NASDAQ:URGN) stock price is $39.19 in the last trading session. During the trading session, URGN stock reached the peak price of $40.35 while $13.79 was the lowest point it dropped to. The percentage change in URGN stock occurred in the recent session was --0.81% while the dollar amount for the price change in URGN stock was -$-0.32.
-
URGN's industry and sector of operation?
-
The NASDAQ listed URGN is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of URGN?
-
James Ottinger | Executive Vice President of Regulatory Affairs & Quality
Michael J. Louie | Chief Development Officer
Timothy Simon | Senior Vice President of Business Development & Portfolio Strategy
Elizabeth A. Barrett | President, Chief Executive Officer & Director
Mark Schoenberg | Chief Medical Officer -
How many employees does URGN have?
-
Number of URGN employees currently stands at 291. URGN operates from 400 Alexander Park Drive, Princeton, NJ 08540, US.
-
Link for URGN official website?
-
Official Website of URGN is: https://www.urogen.com
-
How do I contact URGN?
-
URGN could be contacted at phone #646 768 9780 and can also be accessed through its website. URGN operates from 400 Alexander Park Drive, Princeton, NJ 08540, US.
-
How many shares of URGN are traded daily?
-
The average number of URGN shares traded daily for last 3 months was 814.44K.
-
What is the market cap of URGN currently?
-
The market value of URGN currently stands at $1.91B with its latest stock price at $39.19